Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hematol. May 6, 2014; 3(2): 18-28
Published online May 6, 2014. doi: 10.5315/wjh.v3.i2.18
Ex vivo expansion of hematopoietic stem and progenitor cells: Recent advances
Katsuhiro Kita, Fangming Xiu, Marc G Jeschke
Katsuhiro Kita, Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, TX 77555, United States
Fangming Xiu, Sunnybrook Research Institute, University of Toronto, Ontario, M5S 2W6, Canada
Marc G Jeschke, Ross Tilley Burn Centre, Sunny brook Health Science Centre and Sunnybrook Research Institute and Division of Plastic Surgery, Department of Surgery, University of Toronto, Toronto, M5S 2W6, Canada
Author contributions: All authors solely contributed to this paper.
Supported by Canadian Institutes of Health Research, No. 123336; CFI Leader’s Opportunity Fund, No. 25407; Physicians’ Services Incorporated Foundation - Health Research Grant Program (MGJ)
Correspondence to: Katsuhiro Kita, PhD, Research Scientist of Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555, United States. kakitatemp@yahoo.com
Telephone: +1-212-7460293 Fax: +1-212-7468866
Received: April 17, 2012
Revised: December 7, 2013
Accepted: January 17, 2014
Published online: May 6, 2014

Hematopoietic stem cells (HSCs) have become the most extensively studied stem cells and HSC-based cellular therapy is promising for hematopoietic cancers and hereditary blood disorders. Successful treatment of patients with HSC cells depends on sufficient number of highly purified HSCs and progenitor cells. However, stem cells are a very rare population no matter where they come from. Thus, ex vivo amplification of these HSCs is essential. The heavy demands from more and more patients for HSCs also require industrial-scale expansion of HSCs with lower production cost and higher efficiency. Two main ways to reach that goal: (1) to find clinically applicable, simple and efficient methods (or reagents) to enrich HSCs; (2) to find new developmental regulators and chemical compounds in order to replace the currently used cytokine cocktails for HSCs amplification. In this Editorial review, we would like to introduce the current status of ex vivo expansion of HSCs, particularly focusing on enrichment and culture supplements.

Keywords: Hematopoietic stem cell, Ex vivo expansion, Serum-free culture, Cell surface markers, Enrichment, Stem cell isolation